Related references
Note: Only part of the references are listed.Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Histone deacetylase inhibitors in lymphoma and solid malignancies
Walid Rasheed et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Histone deacetylase inhibitors: Molecular and biological activity as a premise to clinical application
V. Santini et al.
CURRENT DRUG METABOLISM (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma
Sean J. Whittaker et al.
CANCER TREATMENT REVIEWS (2007)
Significant impact of cutaneous T-cell lymphoma on patients' quality of life - Results of a 2005 National Cutaneous Lymphoma Foundation Survey
Marie-France Demierre et al.
CANCER (2006)
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles et al.
CLINICAL CANCER RESEARCH (2006)
EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome
Franz Trautinger et al.
EUROPEAN JOURNAL OF CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
RL Piekarz et al.
BLOOD (2004)
Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome - Clinical prognostic factors and risk for disease progression
YH Kim et al.
ARCHIVES OF DERMATOLOGY (2003)
Histone deacetylase inhibitors in cancer treatment
DM Vigushin et al.
ANTI-CANCER DRUGS (2002)
Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas - The severity-weighted assessment tool (SWAT)
SR Stevens et al.
ARCHIVES OF DERMATOLOGY (2002)
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
RL Piekarz et al.
BLOOD (2001)
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results
M Duvic et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
E Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
